Empawish-L-25/5

Empawish-L-25/5(Empagliflozin 25 mg + Linagliptin 5 mg) Tablet is a well-balanced dual-combination therapy developed for the effective management of type 2 Diabetes Mellitus. It brings together empagliflozin, a proven SGLT2 inhibitor, and Linagliptin, a DPP-4 inhibitor, to provide consistent and complementary blood sugar control. This combination works through two different pathways—one that removes excess glucose through urine and another that helps regulate insulin levels naturally. As a result, it not only helps control blood glucose levels but also offers added cardiovascular and metabolic benefits. It is commonly prescribed to improve glycemic control in adults with Type 2 Diabetes, especially when single-drug therapy is not sufficient.

How Does Empawish-L-25/5 Work?

This combination targets blood sugar control through two independent yet complementary mechanisms:

Empagliflozin (25 mg):

It works at the kidney level by blocking the SGLT2 protein responsible for glucose reabsorption. This leads to the removal of excess glucose through urine, helping to lower blood sugar levels. Additionally, it may support mild weight loss and help reduce blood pressure.

Linagliptin (5 mg):

It acts by inhibiting the DPP-4 enzyme, which helps increase the levels of natural incretin hormones like GLP-1 and GIP. These hormones play an important role in increasing insulin release (when needed) and reducing glucagon levels, thereby maintaining stable blood glucose levels throughout the day.

Together, this dual mechanism helps control both fasting and post-meal blood sugar effectively, with a low risk of hypoglycemia.

Clinical Benefits

Better Glycemic Control: Helps achieve significant reduction in HbA1c levels compared to single therapies

Cardio-Renal Support: Empagliflozin is associated with reduced risk of cardiovascular events and slowing of kidney disease progression

Weight-Friendly: Supports modest weight reduction through calorie loss via glucose excretion

Low Risk of Hypoglycemia: Works through insulin-independent and glucose-dependent pathways

Improved Compliance: Available as a once-daily fixed-dose combination, reducing pill burden

Renal Flexibility: Linagliptin can be used across a wide range of kidney functions without dose adjustment

Dosage & Administration

To be taken as directed by the physician.

It is usually taken once daily, with or without food, preferably in the morning.

Disclaimer

This product should be used under medical supervision only. The information provided here is for educational purposes and is not intended to replace professional medical advice.